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While treatment with aspirin plus clopidogrel may be valid
as an adjunct to percutaneous coronary intervention, other
issues remain to be addressed before routine combination














spirin is effective in reducing the risk of
primary and secondary cardiovascular
events, such as myocardial infarction and
stroke, and is a mainstay of both the adjuvant
treatment of acute coronary syndromes and
other cardiovascular disease, with a minor effect
on reducing the risk of venous thromboembo-
lism. While this impact is widely believed to be
caused by suppression of the platelet, aspirin also
has likely desirable non-platelet effects—for
example, in inhibiting nuclear transcription
initiators such as NFkb (implicated in the
promotion of various genes with pro-inflamma-
tory activity), in protecting low density lipopro-
tein cholesterol from oxidative modification, and
in modulating endothelial dysfunction in athero-
sclerosis. However, the precise value of these
latter mechanisms in vivo and any possible
contribution to a reduction in thrombotic events
is speculative.
Although low to medium dose aspirin (32.5–
75 mg daily) is well tolerated in the majority of
patients, the principle adverse effects are gastro-
intestinal bleeding and haemorrhagic stroke. A
meta-analysis of 16 placebo controlled trials of
aspirin for cardiac and other indications found
that aspirin increased the absolute risk of
cerebral haemorrhage by 12 events per 30 000
person-years of follow up. Thus, the possible
value of aspirin in reducing thrombosis may be
weighed against the risk of bleeding, with the
greatest value being in those at highest cardio-
vascular risk.
1–3
HOW VALUABLE IS ASPIRIN?
Despite the positive attributes of aspirin
described above, several commentators have
expressed other concerns that it may not be
broadly valuable.
4 For example, although recruit-
ing patients with hypertension, the HOT trial
reported no protective effect of aspirin on death,
cardiovascular death, all cardiovascular events,
all strokes, all myocardial infarctions, or silent
myocardial infarctions. Aspirin, however, did
protect against myocardial infarction but at the
cost of an increase in fatal and non-fatal major
bleeds, minor bleeds, and total bleeds. There is
also some evidence that dual use of aspirin and
angiotensin converting enzyme inhibitors in
some subgroups of patients may be of dubious
value, although this may not be true for low dose
aspirin. An additional possible problem with
aspirin is the growing recognition of resistance,
reported to be present in 5–10% of patients with
stable coronary artery disease.
5
Clopidogrel inhibits platelet activity by a route
independent of that of aspirin—that is, irrever-
sibly inhibiting platelet aggregation by selectively
binding to adenylate cyclase coupled adenosine
diphosphate receptors on the platelet surface.
6
One of the first major trials of this agent
(CAPRIE) directly compared 325 mg of aspirin
daily with 75 mg of clopidogrel daily in approxi-
mately 19 000 high risk patients with existing
vascular disease (recent ischaemic stroke
(n = 6431), myocardial infarction (n = 6302),
or peripheral artery disease (n = 6452)).
Overall, patients on clopidogrel had a marginally
cardiovascular better outcome with a relative risk
reduction (RRR) of 8.7% (95% confidence inter-
val (CI) 0.3% to 16.5%, p = 0.043) compared to
aspirin, with an overall safety and side effect
profile at least as good as aspirin.
7 The fact that
clopidogrel and aspirin have different modes of
action opens the potential for trials of added
efficacy. The CURE trial compared the effects of
aspirin alone with a combination of aspirin and
clopidogrel in over 12 500 patients with unstable
angina or suspected myocardial infarction.
8 A
primary outcome (cardiovascular death, non-
fatal myocardial infarction, stroke) occurred in
11.4% of patients on aspirin compared to 9.3% on
both agents (p , 0.001), although major and
minor (but not fatal) bleeding was greater in the
combination group. The sub-study in patients
with acute coronary syndromes undergoing
percutaneous coronary intervention (PCI-
CURE) and the CLASSICS trial provided impor-
tant data that have led to the combination of
aspirin and clopidogrel becoming standard treat-
ment for one month after percutaneous coronary
intervention (PCI) with or without stent implan-
tation.
9–11
The MATCH trial was a randomised, double
blind, placebo controlled trial to compare aspirin
(75 mg/day) with placebo in 7599 high risk
patients with recent ischaemic stroke or transient
Abbreviations: CAMPER, clopidogrel and aspirin in the
management of peripheral endovascular
revascularisation; CAPRIE, clopidogrel versus aspirin in
patients at risk of ischaemic events; CASPAR: clopidogrel
and acetylsalicylic acid in bypass surgery for peripheral
arterial disease; CLASSICS, clopidogrel aspirin stent
international cooperative study; CURE, clopidogrel in
unstable angina to prevent recurrent events; CREDO,
clopidogrel for the reduction of events during observation;
HOT, hypertension optimal treatment; MATCH:
management of atherothrombosis with clopidogrel in
high-risk patients with recent transient ischemic attack or
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who were already receiving clopidogrel 75 mg/day.
12 After 18
months, almost 16% of patients reached the primary end point
in the group receiving aspirin and clopidogrel compared with
almost 17% in the clopidogrel alone group (RRR 6.4%, 95% CI
24.6% to 16.3%). Life threatening bleeding was higher in the
group receiving aspirin and clopidogrel versus clopidogrel alone
(96 (2.6%) v 49 (1.3%); absolute risk increase 1.3%, 95% CI 0.6%
to 1.9%). Major bleeding was also increased in the group
receiving aspirin and clopidogrel, but no difference was
recorded in mortality. The authors concluded that adding
aspirin toclopidogrelin highriskpatientswith recentischaemic
stroke or transient ischaemic attack was associated with a non-
significant reduction in major vascular events. However, the
risk of life threatening or major bleeding was increased by the
addition of aspirin.
CLOPIDOGREL PLUS ASPIRIN IN PATIENTS
UNDERGOING PCI
More recently, the CREDO trial suggested an incremental
benefit of prolonged (one year) use of clopidogrel in addition
to aspirin in 2116 patients undergoing elective PCI.
13 Long
term clopidogrel treatment was associated with a 26.9% RRR
in the combined risk of death, myocardial infarction, or
stroke (95% CI 3.9% to 44.4%; p = 0.02; absolute reduction,
3%). Clopidogrel pre-treatment did not significantly reduce
the combined risk of death, myocardial infarction, or urgent
target vessel revascularisation at 28 days (RRR 18.5%, 95% CI
214.2% to 41.8%; p = 0.23). However, in a pre-specified
subgroup analysis, patients who received clopidogrel at least
six hours before PCI experienced an RRR of 38.6% (95% CI
21.6% to 62.9%; p = 0.051) for this end point compared
with no reduction with treatment less than six hours before
PCI. Risk of major bleeding at one year increased, but not
significantly (8.8% with clopidogrel v 6.7% with placebo;
p = 0.07). The authors concluded that long term (one year)
clopidogrel treatment significantly reduced the risk of
adverse ischaemic events, and that a loading dose of
clopidogrel given at least three hours before the procedure
did not reduce events at 28 days, although subgroup analyses
suggested that longer intervals between the loading dose and
PCI may reduce events.
That these trials have focused on patients with coronary
artery disease (CAPRIE, CLASSICS, CURE, CREDO), periph-
eral artery disease (CAPRIE), or cerebrovascular disease
(CAPRIE, MATCH) is unsurprising. However, most patients
with advanced atherosclerosis in one such vascular territory
generally have disease in another, and those with concurrent
disease in all three such territories (coronary, cerebral, and
peripheral) are at additional risk of a major cardiovascular
event.
14 In this issue of Heart, Mukherjee and colleagues
present a post-hoc analysis of those patients from CREDO
with a high burden of atherosclerosis (that is, of the
peripheral and/or cerebral arteries in addition to coronary
artery disease, thus: multiple arterial disease).
15 They looked
at outcome in 272 patients with multiple arterial disease, of
whom 132 received clopidogrel in addition to aspirin, and
compared them to those 140 patients on aspirin alone. In the
main CREDO trial, the event rate (death/myocardial infarc-
tion/stroke) for all patients on aspirin alone was 11.8%, while
the current study reports a clearly higher rate of 17.4% for
patients with multiple arterial disease, as we would expect.
However, while this difference seems large, direct statistical
comparison is difficult. Similarly, the main CREDO patients
on aspirin plus clopidogrel had an event rate of 8.6%,
compared to a rate of 9.2% in the present subgroup analysis
of those patients with the most widespread disease. This
modest change suggests that additional long term clopidogrel
combination treatment particularly benefits patients with the
most widespread disease. This finding is reminiscent of the
CAPRIE study, where there was evidence that clopidogrel
may be particularly effective at preventing vascular events in
patients with peripheral arterial disease compared to those
with stroke or myocardial infarction.
7
RESISTANCE TO ANTIPLATELET EFFECTS
Clopidogrel is clearly recommended for those patients with
atherosclerotic vascular disease with a contraindication to
aspirin,
9 and combination treatment is valid as an adjunct to
PCI. However, other issues remain to be addressed before
routine combination therapy is recommended for any level of
atherosclerosis. A developing issue of resistance to the
antiplatelet effects of clopidogrel remains.
16 Trials currently
in progress (CASPAR, CAMPER) may answer some of the
questions of efficacy and safety. For the time being the
subanalysis of CREDO data by Mukherjee and colleagues
15
adds further weight to the concept of combination antiplate-
let treatment.
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